India 2014: All About Patents, Pricing And M&As
This article was originally published in PharmAsia News
Executive Summary
The Indian drug industry was in the news for all the obvious reasons. Patents were a key topic between Indian firms and their global counterparts. But a new government also sent out signals that it may examine compulsory license issues, which along with the mega deal between Sun and Ranbaxy kept it all lively.